On 8 April, 2022 Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, reported that it will present new data at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held in New Orleans, United States, between 8-16 April 2022 (Press release, Glycotope, APR 8, 2022, View Source [SID1234611642]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: "The data presented at AACR (Free AACR Whitepaper) shows the potential of targeting GlycoTargets to increase the tumor-selectivity of antibodies. We will present two anti-GlycoTarget antibodies with markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues or blood cells. Additionally, we will present updated in vivo efficacy data for GT-00A x IL15, our TA-MUC1-targeting IL-15 fusion antibody. GT-00A x IL15 is one of the first tumor-targeted immuno-cytokines and has the potential to significantly outperform non-targeted IL-15 immuno-cytokines offering a highly needed alternative in the treatment of several solid-tumor indications."
Poster details are as follows:
Abstract Number: 4542 Download here as of Friday, 8 April 1pm ET / 7pm CET
Title: Carbohydrate-dependent protein binding antibodies with superior tumor-specificity
Category: Poster Section 21: Antibodies and Immune Therapies
Session Start Time: 4/10/2022 1:30:00 PM
Session End Time: 4/10/2022 5:00:00 PM
Abstract Number: 4584 Download here as of Friday, 8 April 1pm ET / 7pm CET
Title: Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties
Category: Poster Section 37: Therapeutic Antibodies 1
Session Start Time: 4/12/2022 9:00:00 AM
Session End Time: 4/12/2022 12:30:00 PM
Abstracts are now available on AACR (Free AACR Whitepaper)’s website located at www.aacr.org. E-posters will be available to registrants of the AACR (Free AACR Whitepaper) Annual Meeting at 1:00 p.m. EDT on Friday, April 8
About GT-00A x IL15
GT-00A x IL15 is a TA-MUC1 targeting IL-15 immuno-cytokine fusion antibody. Cytokines have long been used for cancer therapy to activate the immune system, but side effects and short half-life limit their therapeutic application. The concept of specific targeting to the tumor and tumor microenvironment to exploit the full potential of IL-15 biology is unique within the competitive field of IL-15 (super)agonists. The immuno-cytokine attracts and activates immune cells (e.g., T and NK cells) directly at the tumor site thereby turning an "immune desert" into a "hot" tumor and inducing tumor cell lysis. A comprehensive non-clinical data package is available.